Global pharma major Lupin has launched an authorised generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.

The product is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.   

Headquartered in Mumbai, Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Its products span multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women's health, and are distributed in over 100 markets.

Lupin has 15 state-of-the-art manufacturing sites and seven research centers globally, along with a dedicated workforce of over 24,000 professionals.